For patients who have already been treated for high-grade precancerous lesions, the window for HPV vaccination may have permanently closed. This finding matters because clinicians sometimes administer the nonavalent HPV vaccine after surgical or ablative treatment of anal or vulvar high-grade squamous intraepithelial lesions, hoping it will reduce the high recurrence rates that plague these populations — a practice the VIVA trial's results now call into serious question.
The VIVA trial enrolled 185 adults aged 27–69 who had been successfully treated for anal or vulvar HSIL and were lesion-free at baseline. Participants received either the 9-valent HPV vaccine (Gardasil-9) or placebo at months 0, 2, and 6, with surveillance via high-resolution anoscopy or vulvoscopy at 18 and 36 months, plus serial swabs for HPV DNA. The Data and Safety Monitoring Board halted the trial early for futility: HSIL recurred in 16 vaccine recipients versus 21 placebo recipients — an incidence of 8.1 versus 10.1 per 100 person-years, a non-significant difference (p = .54). HPV persistence rates also trended lower with vaccination (21% vs. 31%) but did not reach statistical significance (p = .20).
This result is biologically coherent but clinically sobering. The 9vHPV vaccine induces neutralizing antibodies that block initial mucosal infection; it was never designed as a therapeutic agent against already-established viral reservoirs or immune-evading persisting infections. Prior smaller trials and observational studies generated mixed signals about post-treatment benefit, and the VIVA trial — with its rigorous double-blind, placebo-controlled design — now provides the clearest evidence that post-treatment vaccination in middle-aged adults does not meaningfully alter recurrence biology. Limitations include a sample size constrained by early termination, limiting power to detect modest effects, and the predominantly older cohort may not generalize to younger, recently treated patients. The practical implication for public health messaging is unambiguous: the vaccine's cancer-preventive value is overwhelmingly front-loaded, before any HPV exposure occurs.